Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab in Anti-MDA5 Antibody-Positive Adult Dermatomyositis
NCT07377058Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Nov 2025
- Primary completion
- Oct 2026
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
Randomised, double-blind trial in dermatomyositis (DM) comparing TCZ with Placebo (2 arms). Primary endpoints: Total Improvement Score improvement at 16 weeks and Interstitial Lung Disease improvement at 16 weeks. Started Nov 2025; status: recruiting.
02
Drugs
tocilizumab
03
Conditions
dermatomyositis (DM)
Beyond the preview
Go deeper on NCT07377058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07377058.